Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...

There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.

Antifibrotic treatments for IPF, such as pirfenidone and nintedanib, are associated with significant side effects impacting quality of life. Despite side effects, patients perceive antifibrotics as ...

IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

Add Yahoo as a preferred source to see more of our stories on Google. German pharma Boehringer Ingelheim has obtained FDA approval for its disease-modifying therapy Boehringer Ingelheim’s Jascayd ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prior to this trial, CS014 had positive outcomes in an ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s ...